PMH42 - COST-UTILITY ANALYSIS OF CARIPRAZINE COMPARED TO RISPERIDONE AMONG PATIENTS WITH NEGATIVE SYMPTOMS OF SCHIZOPHRENIA IN SELECTED NORDIC COUNTRIES
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.1677
https://www.valueinhealthjournal.com/article/S1098-3015(18)34979-9/fulltext
Title :
PMH42 - COST-UTILITY ANALYSIS OF CARIPRAZINE COMPARED TO RISPERIDONE AMONG PATIENTS WITH NEGATIVE SYMPTOMS OF SCHIZOPHRENIA IN SELECTED NORDIC COUNTRIES
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)34979-9&doi=10.1016/j.jval.2018.09.1677
First page :
Section Title :
Open access? :
No
Section Order :
1047